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Objectives: To assess Health Related Quality of Life (HRQoL) in patients receiving 
Home Enteral Nutrition (HEN) using NutriQoL® questionnaire in Spain. MethOds: 
NutriQoL®, a specific questionnaire, developed and validated in Spain, for the assess-
ment of HRQoL of patients receiving HEN regardless of the underlying condition was 
administered to a prospective cohort from 9 Spanish hospitals. It includes 17 pairs 
of items of HEN-related HRQoL grouped in two dimensions: 1) physical functioning 
and activities of daily living; 2) social life aspects, scoring from -51 (worst HRQoL) to 
51 (best HRQoL). Cluster analysis using k-means identified groups of patients with 
similar HRQoL. Results: A total of 140 subjects (61.4% men; mean (SD) age: 62.7 
(15.41) participated. NutriQoL® mean total score was 14.98 (14.86). Dimension 1 and 
2 scored 13.55 (11.71) and 1.40 (4.74). Cancer patients presented lower HRQoL com-
pared to neurological and malabsorption patients (12.76 vs. 18.11 vs. 17.37; p= 0.098). 
Patients receiving oral HEN as a supplement referred higher HRQoL than those 
receiving HEN by gastrostomy or nasogastric tube (19.54 vs. 14.00 vs. 7.02; p< 0.001) 
as their only nutrition route (19.33 vs. 8.18; p< 0.001). Up to 71.4% of patients referred 
HRQoL improvements since the introduction of HEN. Cluster analysis resulted in 
4 groups according to NutriQoL® score. Cluster 1 [32.23 (5.83)]: Neurologic patients 
receiving oral HEN as a supplement. Cluster 2 [18.19 (3.94)]: oncologic disease receiv-
ing HEN by gastrostomy as a supplement. Cluster 3 and 4: [3.9 (4.67) and 12.21 (5.95)]: 
oncologic patients receiving oral HEN as a supplement, with differences in terms of 
severity (Charlson index 2.45 (2.65) vs. 3.14 (2.57). cOnclusiOns: NutriQoL® results 
demonstrated a sample with a fairly good HRQoL, where the introduction of HEN 
had improved their HRQoL. In patients receiving HEN, physical functioning and 
activities of daily living were better predictors than social life domain.
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Objectives: Preventing problems for mothers and babies depends on an opera-
tional continuum of care with accessible, high quality care before and during preg-
nancy, childbirth, and the postnatal period. The objective of this study is to evaluate 
the quality of life of pregnant women attending antenatal clinics in rural and urban 
areas of Delta State, Nigeria. MethOds: A descriptive cross sectional study design 
was used. Six hundred and ninety nine pregnant women attending antenatal clinics 
in selected hospitals were interviewed using a 31 item pretested, structured ques-
tionnaire developed using the World Health Organization Quality of Life (WHOQOL) 
on Pregnancy assessment brief template. Data assessed include socio-demographics 
and questions relating to physical, psychological, social and environmental health 
were used to assess the health related quality of life values in each of the study 
participants. Data collected were analyzed using the Statistical Package for Social 
Sciences (SPSS) software version 16.0. The level of statistical significance was set 
at P< 0.0001. Results: The mean age of the respondent was 27±5.04. The HRQOL 
mean scores were highest for the environmental domain (26.39±5.34) and low-
est for the social relationship domain (11.43±1.81). The overall QOL mean scores 
in the other two domains were: physical health (24.84±3.74), psychological health 
(21.84±3.03). Significant differences were observed in all domains except social rela-
tionship. cOnclusiOns: The health related of life (HRQOL) in pregnant women 
was found to be lower in those living in the rural areas than their counterparts in 
the urban areas in all domains except social relationships.
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Objectives: Mortality and morbidity of very preterm (born < 32 weeks’ gestation) 
and very-low-birth-weight (VLBW, < 1500g) infants impose substantially on finite 
health resources. This study estimated costs of hospital and non-hospital services 
for a cohort enrolled in ProPrems Neuro, of very preterm/VLBW infants from birth 
to 24 months’ age corrected for prematurity. We also tested the sensitivity of results 
to the costing approach used. MethOds: ProPrems Neuro study assesses the 2-year 
outcomes of very preterm/VLBW infants from Australia and New Zealand from 
2007-2011 in a prospective multicentre, double-blinded randomised controlled trial 
of probiotic administration. Infants’ health resource use was collected from medical 
assessment records at birth hospitals, parent report and, with parental consent, 
from Medicare Australia (Government database) for resource use up to 24 months. 
Hospital costs were calculated separately by the Victorian (State) Casemix funding 
approach and the newly implemented national activity-based funding (ABF) algo-
rithm. AR-DRG diagnostic/procedural codes were used to classify inpatient episodes 
by prematurity/birth weight, complications, length of stay (LoS), hospital and patient 
characteristics. Costs were measured in 2013 Australian dollars. Results: 1099 
preterm infants across 10 hospitals were included. Average costs were highest for 
infants with birth weight < 750g: $224,158 with mean LoS 105 days. Cost compari-
son between Casemix and ABF systems showed significantly lower costs using the 
national algorithm. Mean cost difference for the largest participating hospital was 
$9132 (95%CI 5998, 12267; p< 0.001). Final results of infant health service use to 2 
patient group. Following the initial review the tablet-based ePRO version was pilot 
tested with 10 endometriosis patients who were native speakers of UK English. 
The translated versions of the EHP were adapted for ePRO administration and the 
resulting screenshots proofread for accuracy. Results: Feedback from patients 
indicated that some amendments to the formatting and ordering of instructions 
would be beneficial. However, all respondents indicated that the ePRO version of 
the EHP was easy to use and preferable to a paper-based questionnaire. The ePRO 
format posed some difficulties for specific languages which required an adjustment 
to the layout or wording structure. cOnclusiOns: Cognitive debriefing and usabil-
ity testing confirmed that the ePRO version of the questionnaire was an accurate 
representation of the original paper version. This was achieved via cooperative 
input at the initial review stage to ensure that all aspects were considered and close 
collaboration throughout the project to find appropriate solutions to the challenges 
posed by the ePRO administration of the EHP.
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Objectives: The objective of this study is to determine which physical assess-
ment Clinical Outcomes Assessment (COA) questionnaire items are most translat-
able. MethOds: Eighteen (18) physical assessment items were analyzed, using 
back-translations to determine conceptual equivalency with the source text. 
Previous studies have regarded 80% source conceptual equivalency as a translat-
ability benchmark. Translator feedback regarding cultural appropriateness also 
influenced whether certain physical assessment items were optimal for use in ques-
tionnaires, as some items might be translatable, but not appropriate for the target 
country. Results: Physical assessment items were grouped into three categories: 
highly translatable, moderately translatable, and problematic. Highly translatable 
examples, “running errands,” “getting around town” and “washing yourself” were 
translated with conceptual equivalency 100% of the time, and were considered 
culturally appropriate for all languages. Moderately translatable items, such as 
“taking a trip” may be misconstrued, as the distance implied may differ across 
languages. “Bathe yourself” was translated with 87% conceptual equivalency, and 
may be misunderstood as “taking a bath,” when the intention is to clean oneself. 
Problematic items, such as “going out,” translated with conceptual equivalency 
only 76% of the time, requiring a destination or activity to be comprehensible in 
other languages. “Walking a block,” although achieving 84% conceptual equivalency, 
is not applicable nor understood in many languages. When measuring distance 
walked, it is recommended to be specific, using examples such as 100 meters or 
a kilometer. cOnclusiOns: Specific concepts appear to be more translatable 
and universal, such as “getting around town” and “walking 100 meters. ” Items 
left open for interpretation, such as “bathing yourself” or “taking a trip” can cause 
moderate translation difficulties. Additionally, many languages cannot coherently 
translate less specific items, such as “going out,” or translate culturally specific 
items. Although “walking a block” is translatable, such an example is unlikely to be 
understood in many languages.
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Objectives: The measurement of the degree of pain and the exploration of influ-
encing factors to compare data about the evaluation of postoperative pain given 
patients and nurses on a numeric scale. The connection between BMI index, age 
and verification of need for opiate associated with BMI was evaluated. Our aim 
was to measure whether nurses underestimate the level of pain in patients as 
well to show the advantages of multimodal analgesia and the additional opiate 
needs. MethOds: The survey was conducted between the 1st November and 15th 
of December in 2013 among 40 patients who had surgery and 10 nurses dealing with 
them afterwards. Data was collected at the sub intensive ward of the Department 
of Obstetrics and Gynaecology, University of Pécs. The analysis of results was 
performed with MO Excel 2007 program. For data analysis absolute and relative 
frequency, Chi-square test, two-sample t-test, correlation and linear regression 
analysis besides the significance level p< 0,05. Results were presented with main 
confidence interval. Results: Nurses underestimated the patients’ pain value 
(p= 0,011). Tight and continuous connection with the patient’s vital parameters had 
not been proved (p> 0,05). Connection was not found between the age and BMI index 
of the patients (p= 0,134), however in case of the mostly overweight sample group 
the need for opiate wasn’t increased (p= 0,62). It is shown by the survey that open 
surgeries aren’t result in higher pain value which was not significant after adequate 
analgesia (p> 0,05). The benefit of multimodal therapy in analgesia had been proved, 
although it had not resulted in decreased need for opiate (p= 0,807). cOnclusiOns: 
It is essential to conduct a survey on the knowledge of health care workers in the 
future and to organize possible workshops and create protocols. Moreover, pain 
should be monitored minimum three times a day (Shugarman LR., 2010, Canada).
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cally significant (α ≤ 0.05). In contrast, 47 medicines had an average BPS price 
after CAP significantly lower or equal to the average BPS price before CAP (α ≤ 
0.05). cOnclusiOns: It is concluded that this CMED legislation is economic and 
social efficient.
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Objectives: The aging of the population and the increase of chronic disease 
patients represent the current medical and socio-economic challenges. In 2008, 
facing considerable increase of medicines cost in nursing homes (NH) in the 
canton of Vaud (Switzerland), professionals around the resident were invited to 
develop a collaborative pharmacy practice model derived from the successful 
experimentation in the canton of Fribourg. The intervention called Quality Circle 
in NH is an evidence-based program with a direct influence on the prescriber, that 
promotes team based care and clinical guidelines. The model has showed sustain-
able evidence of the cost containment of medicines without affecting the quality of 
care. The objective of this study was to assess the first results of economic impact 
of the program in NH engaged between 2009 and 2012. MethOds: Individual 
data by NH resident was derived from community pharmacists’ invoice and from 
resident admission data. The evolution of the daily mean drug cost per resident 
was compared to the evolution of the daily mean drug cost of the population 
over 65 years old in primary care from cantonal pharmacy invoice (Swiss Health 
Observatory, OBSAN). Results: Between 2009 and 2012,13 NH were entered into 
the program (601/6’492 beds, 9.3%), between 9 and 11 NH were monitored. In 2012, 
the mean age of residents was 88 (SD 7.3) years old; 78% were women. From 2009 
to 2012 the daily mean drug cost per resident of the program decreased to 10.3% 
from 6.8 to 6.1 EUR, representing a clear reduction compared to cantonal invoice 
that record an increase of 0.59%. cOnclusiOns: The monitoring of the program 
shows first positive results due to the reduction of drug costs. Nevertheless, this 
model has an operating cost. The next step will be to determine the break even 
point of the intervention.
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Objectives: To assess the patterns and factors associated with prescription 
of FDA classified C, D and X category drugs (unsafe medications) during preg-
nancy. MethOds: Cross-sectional analysis was conducted of pregnant women aged 
20 and 49 years using data from the Medical Expenditure Panel Survey (MEPS) for the 
years 2009 and 2011. Difference in the demographic variables, socioeconomic status, 
access to health care, and chronic conditions were tested for the use of safe medi-
cations. All analyses accounted for the complex survey design of MEPS. Results: 
The study sample consisted of 1603 pregnant women (whites [595 (58.8%)], married 
[924 (66.3%)], employed [918 (64.5%)], no chronic illness [1103 (65%)]). A total of 413 
(28.3%) women utilized medication of FDA category CDX. The use of the category 
C medications was highest [337 (23.4%)] drugs followed by category D [101 (6.9 %)], 
and category X [64 (4.4)]. Women with chronic illness [adjusted Odds Ratio (aOR) = 
1.61; 95% CI = 1.03, 2.52, P < 0.001], having fair or poor perceived health status (aOR = 
1.95; 95% CI= 1.15, 3.31, P < 0.05), doing regular physical activity (aOR = 1.50; 95% CI= 
1.12, 2.01, P < 0.01) were more likely to receive unsafe medication, while pregnant 
women with less than higher secondary education (OR = 0.30; 95% CI = 0.11,0. 81, 
P < 0.05), with near poor (aOR: 0.53, 95% CI: 0.31, 0.91, P< 0.05) or middle income (aOR: 
0.62, 95% CI: 0.40, 0.95, P < 0.05), were less likely to receive unsafe medications. There 
were no differences rates of unsafe medications use by age, race, marital status, 
employment status, mental health, and smoking status. cOnclusiOns: Nearly 
one-third of all pregnant women used FDA category CDX drugs. Interventions should 
be carried out to reduce utilization of FDA CDX especially among the women with 
chronic conditions and poor health status.
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Objectives: A model was designed to evaluate infertility treatment protocols and 
examines the medical and pharmacy budget impact from a patient and health 
plan perspective. MethOds: An Excel-based platform (Microsoft Excel 2010) was 
designed to model the cost and expected number of pregnancies associated with 
the following advanced infertility treatments: natural cycle intrauterine insemina-
tion (IUI), IUI with clomiphene citrate (IUI-C), IUI with gonadotropins (IUI-G), in vitro 
fertilization (IVF) and IVF with intracytoplasmic injection (IVF+ICSI). The model is 
designed to customize inputs within key parameters including population, treat-
ment strategies and health plan coverage. Standard fertility treatment strategy can 
choose to enter one of five standard first line treatment pathways including IUI, 
IUI-C, IUI-G, IVF or IVF+ICSI. Fast track fertility treatment strategy does not include 
the use of IUI-G. Health plan coverage allows end user to input drug coverage (yes/
no, copayment per cycle and patient coinsurance) and procedure coverage (yes/no, 
number of cycles covered, copayment, number of covered doctor visits per cycle 
and patient coinsurance). Results: Default model population of women initiating 
fertility treatment is 1,555. The total cost to the health plan per year (health plan 
years corrected age will be presented in November 2014 with follow-up comple-
tion and data release from Government database by August 2014. cOnclusiOns: 
Preterm infants showed high services use including hospitalisation, with associated 
high costs. Costs vary by patient characteristics and costing approach. This study’s 
results should inform effective resource planning of neonatal health services and 
development of future prevention interventions aimed at preterm birth.
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Objectives: Topical testosterone agents (TTAs) are commonly used to raise low 
serum levels of testosterone in men. After initiating at a recommended starting dose 
(RSD), patients may undergo dose titration to achieve an appropriate maintenance 
dose. The objective of this study was to compare daily maintenance doses and 
costs of treatment with TTAs from US payer perspective in adult men diagnosed 
with Hypogonadism (HG). MethOds: Adult men with a HG-associated diagno-
ses initiated at the RSD with Axiron® (Lilly USA, LLC; RSD 60mg per day; N= 209), 
AndroGel® 1% (AbbVie Inc.; 50mg per day; N= 614), AndroGel® 1.62% (AbbVie Inc.; 
40.5mg per day; N= 235), or Testim® (Auxilium Pharmaceuticals, Inc.; 50mg per day; 
N= 558) between January 1, 2011 and March 31, 2012 were identified in a database 
of commercially insured beneficiaries. Patients were required to have continuous 
eligibility and no claims of the index therapy in 12 months prior to and at least 1 
month of continuous eligibility following initiation. Baseline demographic charac-
teristics, Charlson Comorbidity Index (CCI), comorbidities, and testosterone use 
were compared using chi-squared test for categorical variables and Wilcoxon rank-
sum test for continuous variables. Mean dose was estimated per-person per-day 
(PPPD). Risk-adjusted dose and payer costs PPPD were estimated with a generalized 
linear model. Results: Maintenance dose was attained at month 4. Mean dose 
PPPD in month 4 was 68.45mg, 56.68 mg, 51.18mg, and 59.24mg and risk-adjusted 
dose PPPD was 113.3%, 113.5%, 126.3%, and 118.7% of RSD for Axiron, AndroGel 
1% (non-significant vs. Axiron), AndroGel 1.62% (P< 0.001 vs. Axiron), and Testim 
(P= 0.047 vs. Axiron), respectively. Risk-adjusted third-party payer costs PPPD were 
$7.49, $9.49, $10.39, and $9.59 (all P< 0.001 vs. Axiron), respectively. cOnclusiOns: 
Maintenance dose as a proportion of RSD was the least among Axiron and AndroGel 
1% patients, while third-party payer costs for the maintenance dose were lowest 
among Axiron patients.
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Objectives: The aim of this work is measure the efficiency of public medicine 
purchase considering competitive markets applied by the rule that establishes 
PMVG. MethOds: The competitive market was defined as more than 5 (five) phar-
maceutical manufactories. Two lists were built, one with PMVG (PMVG databank), 
established by CMED, and the other list contains the public prices acquisitions 
before and after the enacted CAP legislation (Health Price Bank – BPS databank). The 
lists were separated in two groups. The first contains the prices of PMVG databank 
and BPS databank between 2004 and 2006 (group 1), and the second complains 
the prices for the period between 2007 and 2012 (group 2). The comparison of two 
groups, before CAP (group 1) and after CAP (group 2), was conducted by Student 
t-test one-tailed of the mean medicine prices (significance level of 5%, assuming 
unequal variances). Results: The list resulted in a selection of 29 medicines. Six 
(6) medicines had an average BPS price before CAP less than or equal to the aver-
age BPS price after CAP, however, only 1 was statistically significant (α ≤ 0.05). In 
contrast, 23 medicines had an average BPS price after CAP significantly lower or 
equal to the average BPS price before CAP, but only 5 (five) no statistically significant 
(α ≤ 0.05). cOnclusiOns: For competitive market we have observed efficiency loss 
by application of CMED legislation.
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Objectives: The aim of this work is measure the efficiency of this rule that estab-
lished PMVG for public medicine purchase. MethOds: Two lists were built, one 
with PMVG (PMVG databank), established by CMED, and the other list contains 
the public prices acquisitions before and after the enacted CAP legislation (Health 
Price Bank – BPS databank). The lists were separated in two groups. The first con-
tains the prices of PMVG databank and BPS databank between 2004 and 2006 
(group 1), and the second complains the prices for the period between 2007 and 
2012 (group 2). The comparison of two groups, before CAP (group 1) and after CAP 
(group 2), was conducted by Student t-test one-tailed of the mean medicine prices 
(significance level of 5%, assuming unequal variances). Results: CMED imple-
mented The Price Adequacy Coefficient (CAP) by publishing the Resolution CMED 
nº 04 on 18thof December of 2006. It is a mandatory minimum discount to be 
applied by pharmaceutical companies and distributors in the Factory Price of 
medicines (PF) authorized, resulting on a public price cap (PMVG). There is no 
evidence of the efficiency, or the real need for this regulatory activity performed 
by CMED geared to the drug public acquisitions. The list resulted in a selection of 
68 medicines. Fourteen (14) medicines had an average BPS price before CAP less 
than or equal to the average BPS price after CAP, however, only 4 were statisti-
